Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > January 10, 2023
Daily News
January 10, 2023
- Official Margin Proposal Only Realistic for Partial Introduction: Crecon President
January 10, 2023
- Top-Tier Pharma Companies, Mid-Sized Peers Mixed on Special PMP Step: New Year Confab
January 10, 2023
- Leqembi Likely to Hit Peak Sales after 2030, US$26,500 Price Matches Value: Eisai CEO
January 10, 2023
- Lecanemab Nabs Accelerated Approval in US, Set to Hit Market Late January
January 10, 2023
- Takeda’s TAK-755 Shows Promising PIII Interim Data for Ultra-Rare Blood Clotting Disorder
January 10, 2023
- Kaken Earns Japan Rights to CAH Med, Poised to Boost Rare Disease Biz
January 10, 2023
- Nippon Shinyaku Launches Open Innovation-Driven Drug Discovery Hub in US
January 10, 2023
- Fujifilm US Subsidiary Licenses iPSC Platform to Novo
January 10, 2023
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…